Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 4/20 | 0.50 |
| ▸ | CCND1 | P24385 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258072 | 1.00 | HTR6 (0.59) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL28021795 | 0.86 | HTR6 (0.59) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL31257891 | 0.86 | HTR6 (0.59) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL31258193 | 0.81 | HTR6 (0.70) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL3844137 | 0.81 | HTR6 (0.70) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL6085680 | 0.81 | HTR6 (0.65) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL1104768 | 0.81 | HTR6 (0.55) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL31258087 | 0.81 | HTR6 (0.55) | HTR6KMT2APLAUCDK4CCND1 | |
| SCHEMBL30364634 | 0.80 | HTR6 (0.51) | HTR6PLAUHDAC1HDAC2HDAC8 | |
| SCHEMBL6085996 | 0.80 | HTR6 (0.58) | HTR6KMT2APLAUCDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6987122-B2 | 2-(1H-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2006-01-17 | — | — | US | disclosed |
| EP-1244652-B1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | CELL THERAPEUTICS EUROPE SRL (IT) | 2005-08-24 | — | — | EP | disclosed |
| US-6753342-B2 | ANTICARCINOGENIC AGENTS FOR LUNG AND COLON CANCER TREATMENT | NOVUSPHARMA S.P.A. (IT) | 2004-06-22 | — | — | US | disclosed |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | NOVUSPHARMA S.P.A. (IT) | 2004-02-12 | — | — | US | disclosed |
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | NOVUSPHARMA S.P.A. (IT) | 2003-08-21 | — | — | US | disclosed |
| EP-1322646-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | Novuspharma S.p.A. (IT) | 2003-07-02 | — | — | EP | disclosed |
| EP-1244652-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | Cell Therapeutics Europe S.R.L. (IT) | 2002-10-02 | — | — | EP | disclosed |
| WO-2002008225-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETIC ACID AMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001047916-A1 | 2-(1H-INDOL-3-YL)-2-OXO-ACETAMIDES WITH ANTITUMOR ACTIVITY | NOVUSPHARMA S.P.A. (IT) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158153-A1 | 2-(1h-indol-3-yl)-2-oxo-acetamides containing a thiophene or furan ring; anticarcinogenic agents particular against solid tumors of colon and lung | IDO2, IDO1, TXNRD2 | HTR6 2619/4885KMT2A 1607/4885PLAU 4791/4885 |
| US-20040029858-A1 | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | IDO1, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HTR6 2122/4885KMT2A 453/4885PLAU 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.